Codexis Appoints Singapore Laboratories Managing Director
Codexis, Inc.announced the appointment of Thomas Daussmann, Ph.D., to the new position of Vice President and Managing Director of Codexis Laboratories Singapore Pte. Ltd. CLS is the company's first facility in Asia. Dr. Daussmann will report to Alan Shaw, Ph.D., President and CEO.
Since 1999, Dr. Daussmann has served as managing director of Julich Chiral Solutions, (previously JFC-Julich Fine Chemicals), the Codexis enzyme and intermediates manufacturing facility in Germany. JFC was acquired by Codexis in 2005. Dr. Daussmann has authored or co-authored more than 25 scientific publication articles on biocatalytic manufacturing, and is named on numerous patent applications in the field. He received his bachelor's degree in biology from the University of Karlsruhe, his master's degree in biotechnology from the University of Kaiserslautern, and his Ph.D. degree in microbiology from the Research Centre in Julich (all in Germany). His doctoral study was conducted under the supervision of Professor Christian Wandrey, University of Bonn, a respected authority in biotechnology research.
Build-out has begun on the 20,000-square-foot research center in the Science Park III area of Singapore. It is scheduled to open this fall as an expansion of Codexis U.S. research and development operations. CLS will be able to house up to 80 research and operations personnel. Bio*One Capital Pte. Ltd. of Singapore led the Codexis Series D private financing round in August 2006.
Other news from the department people
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
